Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2024 Nov 29;15:1513076. doi: 10.3389/fimmu.2024.1513076

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2024 Miao, Dong, Zhou, Thiel, Li, Cai, Yuan, Wang, Jin, Yang, Wang, Frey, Gaipl, Ma and Zhou

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

FGF12 and KLHL29 expression correlates with poor prognosis and tumor progression in ESS. (A) Scatterplot demonstrating the results of KEGG enrichment analysis of differentially expressed genes of Str1 between LG-ESS and HC. (B) Heatmap demonstrating the results of Cox regression analysis and survival analysis for specific genes based on bulk transcriptome data of ESS patients. (C) Featureplot demonstrating the expression of FGF12 and KLHL29 genes in different cellular subpopulations of LG-ESS. (D, E) Results of survival analysis based on FGF12 (D) and KLHL29 (E) expression in ESS patients, with overall survival on the left and progression-free survival on the right (GSE128630). (F, G) Results of GSEA enrichment analysis after differentiating patients into high and low expression groups based on FGF12 (F) and KLHL29 (G) gene expression in ESS patients, with significantly activated pathways in the high expression group on the left and significantly inhibited pathways on the right.